|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Clinical Trials for: KALETRA
First 100 trials shown — repeat this search at ClinicalTrials.gov| Title | Status | Condition | Last Changed | External link |
|---|---|---|---|---|
| Lopinavir Capsules to Kaletra or Invirase Tablets | Completed | HIV Infections | July 15, 2011 | link |
| Comparison of Liquid Kaletra and Low Dose Kaletra Tablets | Completed | HIV Infections | December 19, 2012 | link |
| KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18) | Recruiting | Antiretroviral Therapy in HIV-1 Infected Children | February 2, 2012 | link |
| Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole | Completed | Pharmacokinetics of Isavuconazole; Pharmacokinetics of Lopinavir/Ritonavir; Healthy Volunteers | November 7, 2012 | link |
| Lopinavir/Ritonavir (Kaletra) PK in Children | Completed | HIV/AIDS Treatment; HIV Infections | June 2, 2012 | link |
| Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients | Completed | HIV Infection | April 1, 2008 | link |
| A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort | Completed | HIV-1; AIDS | April 4, 2007 | link |
| Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients | Completed | HIV Infection | July 9, 2008 | link |
| GSK706769/KALETRA Drug-drug Interaction Study | Completed | Healthy Subjects; Infection, Human Immunodeficiency Virus | June 21, 2012 | link |
| The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet | Completed | Pregnancy; HIV | May 11, 2011 | link |
| Evaluation of Kaletra Therapy Over the Long-term | Completed | Human Immunodeficiency Virus | August 9, 2011 | link |
| Drug Use Investigation of Kaletra | Completed | Human Immunodeficiency Virus | January 31, 2012 | link |
| Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients | Completed | HIV Infections | February 19, 2008 | link |
| Special Investigation of Kaletra in Pregnant Women | Completed | Human Immunodeficiency Virus | December 9, 2011 | link |
| Lopinavir (LPV) Dose Reduction | Completed | HIV-1 Infections | July 8, 2010 | link |
| Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir) | Completed | HIV Infections | October 19, 2012 | link |
| Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy | Active, not recruiting | HIV Infections; Pregnancy | March 22, 2012 | link |
| Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir | Completed | HIV Infections | December 3, 2010 | link |
| Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China | Completed | HIV-1 Infections | July 7, 2011 | link |
| Kaletra Monotherapy in HIV/HCV Co-infected Subjects | Completed | HIV Infections | May 28, 2012 | link |
| ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial | Completed | HIV-1 | November 18, 2011 | link |
| Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa | Active, not recruiting | HIV | March 16, 2010 | link |
| Raltegravir Kaletra Pharmacokinetics | Completed | Healthy | June 16, 2008 | link |
| Kaletra in Combination With Antiretroviral Agents | Recruiting | Human Immunodeficiency Virus | May 21, 2013 | link |
| Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily | Recruiting | HIV | April 19, 2013 | link |
| Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) | Completed | Human Immunodeficiency Virus Infection | February 13, 2012 | link |
| Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score | Completed | HIV Infection | January 2, 2013 | link |
| Kaletra and Viread in Antiretroviral Naïve Patients | Terminated | HIV Infections | October 9, 2012 | link |
| Metabolic Effects of Switching Kaletra to Boosted Reyataz | Completed | HIV Infections | March 5, 2010 | link |
| Safety and Effectiveness of World Health Organization Dosing Guidelines of Lopinavir/Ritonavir for Children | Recruiting | HIV | May 3, 2013 | link |
| Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin | Not yet recruiting | AIDS; Tuberculosis | October 2, 2012 | link |
| Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet | Recruiting | Human Immunodeficiency Virus | April 16, 2013 | link |
| Dose Reduction of Lopinavir in Children | Completed | HIV Infections | April 22, 2009 | link |
| Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients | Completed | Human Immunodeficiency Virus | March 14, 2013 | link |
| Surveillance of Kaletra in Korean Patients | Enrolling by invitation | HIV-1 Infection | April 26, 2013 | link |
| Kaletra-isentress Treatment Evaluation | Completed | HIV Infections | March 16, 2012 | link |
| Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil | Completed | Healthy Volunteers | March 13, 2012 | link |
| Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study | Recruiting | HIV | October 8, 2008 | link |
| Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) | Recruiting | HIV Infections | September 23, 2010 | link |
| Kaletra Sex/Gender Pharmacokinetics (PK) Study: A Switch From Twice Daily to Once Daily Lopinavir/Ritonavir | Recruiting | HIV Infections | February 9, 2006 | link |
| Pharmacokinetic Study of Two Generic co-Formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF) | Completed | HIV Infections | February 24, 2009 | link |
| Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects. | Completed | HIV Infection | June 8, 2012 | link |
| An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin | Recruiting | HIV Infection; Tuberculosis | June 18, 2009 | link |
| Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women | Completed | HIV Infections | April 3, 2012 | link |
| A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects | Completed | HIV Infections | September 28, 2006 | link |
| Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure | Completed | HIV; AIDS; Lopinavir; Treatment Failure | May 10, 2013 | link |
| A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects | Recruiting | HIV Infections | February 12, 2010 | link |
| A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen | Active, not recruiting | HIV Infections | September 26, 2012 | link |
| High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease | Recruiting | HIV; AIDS | September 18, 2006 | link |
| Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients | Recruiting | HIV Infections | July 18, 2005 | link |
| Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses. | Completed | Acquired Immunodeficiency Syndrome | March 2, 2011 | link |
| Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r | Completed | HIV/HCV Co-infection; HIV Infections | March 21, 2013 | link |
| MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED) | Terminated | HIV Infection | February 28, 2012 | link |
| Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy | Completed | HIV Infection; Lipodystrophy; HIV Infections | March 21, 2013 | link |
| Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children | Recruiting | HIV-1 Infection | February 3, 2011 | link |
| Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects | Completed | Human Immunodeficiency Virus Infections | February 3, 2012 | link |
| Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC | Active, not recruiting | HIV Infection; HIV Infections | February 29, 2012 | link |
| Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects | Completed | Human Immunodeficiency Virus Infections | April 7, 2011 | link |
| Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir) | Active, not recruiting | Drug Interactions; Human Immunodeficiency Virus | July 9, 2012 | link |
| Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients | Completed | HIV Infections | July 19, 2011 | link |
| Ritonavir-boosted Lopinavir Monotherapy | Completed | HIV | November 10, 2011 | link |
| A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects | Terminated | HIV; Tuberculosis | October 29, 2010 | link |
| Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva | Active, not recruiting | HIV Infections | December 21, 2011 | link |
| Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in co-Infected HIV/HCV Patients | Terminated | HIV Infections | April 22, 2009 | link |
| Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir | Terminated | HIV Infections | April 5, 2013 | link |
| Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting | Completed | HIV-1 Infection | January 17, 2013 | link |
| GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir | Completed | Healthy Volunteer | February 20, 2012 | link |
| Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) | Completed | Human Immunodeficiency Virus Infection | April 30, 2013 | link |
| ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects | Completed | HIV Infections | April 2, 2008 | link |
| Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects | Completed | HIV Infections; Dyslipidemias; Glucose Metabolism Disorders; Metabolic Diseases; Lipodystrophy; Cardiovascular Disease | April 11, 2012 | link |
| Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use | Completed | HIV-1 Patients | October 10, 2011 | link |
| Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy | Active, not recruiting | HIV Infections | February 12, 2010 | link |
| Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease | Terminated | Acquired Immune Deficiency Syndrome | January 16, 2013 | link |
| Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients | Active, not recruiting | HIV Infections | February 12, 2013 | link |
| Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients | Terminated | HIV Infection | February 5, 2009 | link |
| Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis | Not yet recruiting | Primary Biliary Cirrhosis | June 6, 2012 | link |
| GW873140 In Combination With Kaletra In HIV Infected Subjects | Terminated | Human Immunodeficiency Virus I Infection; HIV Infection | March 17, 2011 | link |
| Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens | Completed | HIV Infections | October 5, 2007 | link |
| A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules | Not yet recruiting | HIV Infection | March 17, 2006 | link |
| Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV | Completed | HIV Infection | June 3, 2010 | link |
| Pilot Assessment of Lopinavir/Ritonavir and Maraviroc | Recruiting | HIV Infections; Acquired Immunodeficiency Syndrome | February 22, 2010 | link |
| TDM of Generic Lopinavir/Ritonavir 200/50 mg | Active, not recruiting | HIV | November 30, 2010 | link |
| KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks | Completed | HIV Infection; Infection, Human Immunodeficiency Virus | May 12, 2011 | link |
| BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r) | Terminated | HIV Infections | December 6, 2010 | link |
| Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy | Completed | HIV Infections | August 23, 2012 | link |
| A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects | Withdrawn | HIV Infection; Hepatitis C | July 26, 2006 | link |
| GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection | Completed | HIV Infections | September 23, 2011 | link |
| Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients | Active, not recruiting | HIV Infections | September 8, 2010 | link |
| Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects. | Completed | Hepatitis C; Thrombocytopenia | April 7, 2011 | link |
| Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy | Terminated | HIV Infection | November 19, 2008 | link |
| Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs) | Completed | HIV Infection | December 13, 2011 | link |
| Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma | Active, not recruiting | Hodgkin Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma | May 22, 2012 | link |
| Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women | Completed | HIV Infections | October 26, 2012 | link |
| Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | Active, not recruiting | Brain Tumor; Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Oligodendroglioma; Brain Stem Glioma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Mixed Glioma | August 2, 2012 | link |
| Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding | Active, not recruiting | HIV Infections | November 7, 2012 | link |
| Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors | Completed | Endothelial Dysfunction | August 29, 2008 | link |
| Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects | Active, not recruiting | HIV Infections | September 1, 2011 | link |
| Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals | Completed | HIV Infections | July 7, 2011 | link |
| Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in HIV | Not yet recruiting | HIV Infection; Tuberculosis | December 4, 2012 | link |
| Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL) | Active, not recruiting | HIV-infected Children | July 24, 2012 | link |
Source: ClinicalTrials.gov
This preview shows a limited data set. Complete access is available with a Subscription
« Back to Dashboard
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc